News Detail

This Verve Therapeutics Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Wednesday

Benzinga · 06/18 12:34

Listen to the news

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Jefferies analyst Roger Song downgraded the rating for Verve Therapeutics, Inc. (NASDAQ:VERV) from Buy to Hold and lowered the price target from $28 to $11. Verve Therapeutics shares closed at $11.38 on Tuesday. See how other analysts view this stock.
LifeSci Capital analyst Cory Jubinville downgraded Verve Therapeutics, Inc. (NASDAQ:VERV) from Outperform to Market Perform and announced a $12 price target. Verve Therapeutics shares closed at $11.38 on Tuesday.. See how other analysts view this stock.
Citigroup analyst Vicky Wei downgraded Smart Share Global Limited (NASDAQ:EM) from Buy to Neutral but raised the price target from $1 to $1.25. Smart Share Global shares closed at $1.12 on Tuesday. See how other analysts view this stock.
HC Wainwright & Co. analyst Mitchell Kapoor downgraded Verve Therapeutics (NASDAQ:VERV) from Buy to Neutral and maintained the price target of $13.5. Verve Therapeutics shares closed at $11.38 on Tuesday. See how other analysts view this stock.

Considering buying VERV stock? Here’s what analysts think:

Read This Next:

Top 3 Health Care Stocks That Are Ticking Portfolio Bombs

Photo via Shutterstock

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.

What's Trending

No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.